🇺🇸 FDA
Pipeline program

CEFTRIAXONE VIATRIS 1 g, poudre pour solution injectable, Clarithromycine EG 500 mg comprimés pelliculés, MÉTRONIDAZOLE ARROW 500 mg, comprimé pelliculé sécable

APHP220670

Phase 3 small_molecule active

Quick answer

CEFTRIAXONE VIATRIS 1 g, poudre pour solution injectable, Clarithromycine EG 500 mg comprimés pelliculés, MÉTRONIDAZOLE ARROW 500 mg, comprimé pelliculé sécable for Pregnant women with singleton pregnancies hospitalized for threatened late miscarriage with intact membranes is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Pregnant women with singleton pregnancies hospitalized for threatened late miscarriage with intact membranes
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials